Immunic Schedules Virtual R&D Day for Progressive Multiple Sclerosis

Immunic, Inc., a biotechnology firm listed on Nasdaq as IMUX, will conduct a virtual Research and Development Day on November 5, 2026. The event will center on progressive multiple sclerosis (MS) and feature presentations by prominent experts along with Immunic's management team. The focus will be on discussing unmet needs and novel therapeutic approaches to progressive MS.

Immunic plans to showcase the potential of its investigational drug, vidofludimus calcium (IMU-838), specifically its application in progressive MS. As the Phase 3 trial for this drug approaches, the event will delve into its unique characteristics, including neuroprotective effects and involvement as a nuclear receptor-related activator, which supports further evaluation in progressive MS.

Industry experts Jiwon Oh, M.D., Ph.D., from the University of Toronto, and Maria Pia Sormani, Ph.D., from the University of Genoa, will join the session. They will offer insights into progressive MS treatments and new therapy developments.